Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LUNAR-4: Pilot, Single Arm, Open-Label, Multinational Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) Previously Treated With a PD-1/PD-L1 Inhibitor and Platinum-Based Chemotherapy

NCT06558799 is registered in ClinicalTrials.gov with NovoCure GmbH as lead sponsor.

NCT NCT06558799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06558799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LUNAR-4: Pilot, Single Arm, Open-Label, Multinational Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) Previously Treated With a PD-1/PD-L1 Inhibitor and Platinum-Based Chemotherapy
Lead sponsor
NovoCure GmbH
Phase
Phase 2
Overall status
Terminated
Start date
October 14, 2024
Completion date
February 23, 2026
Enrollment
31 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)